Quick Answer
Transcode Therapeutics, Inc. reported Total Assets of $7.29 million for the year ending 2024.
- Transcode Therapeutics, Inc. showed an increase of +41.1% in Total Assets from 2023 to 2024.
- This data is from Transcode Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2020 to 2024 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2021: $1.52 million | Q3 2021: $25.36 million | Q1 2022: $18.85 million | Q2 2022: $14.16 million | Q3 2022: $12.02 million | Q1 2023: $5.59 million | Q2 2023: $5.88 million | Q3 2023: $10.23 million | Q1 2024: $7.29 million | Q2 2024: $4.82 million | Q3 2024: $3.94 million | Q4 2024: $7.29 million | Q1 2025: $13.19 million | Q2 2025: $8.27 million | Q3 2025: $5.23 million.
- Over the full 5 years of available data (2020 to 2024), Transcode Therapeutics, Inc.'s Total Assets has grown by 591.2%.
- Historical annual values: Fiscal year 2024: $7.29 million | Fiscal year 2023: $5.17 million | Fiscal year 2022: $7.59 million | Fiscal year 2021: $22.94 million | Fiscal year 2020: $1.06 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: